Noom Med runs two tracks, and only one of them involves prior authorization at all.
The branded track (Wegovy, Zepbound, Ozempic, Mounjaro) goes through real prior authorization — commonly up to a 2-week initial wait, with a 90-day appeal window if denied. The compounded GLP-1Rx track skips insurance entirely.
If you're tired of waiting on a coverage decision, Luma Health's flat $297/month tirzepatide has no prior authorization step at all.
Noom Med runs two separate tracks, and which one you land on changes your prior authorization experience completely. Knowing which track you're actually on, and what that means for your timeline, is the first thing to sort out before anything else.
Noom Med's Two Tracks, and Why They Matter
Noom Med for branded medications is built around insurance: the membership itself runs roughly $39 to $69 to start and about $99/month afterward, but that fee doesn't include the medication. If your clinician prescribes a branded GLP-1 like Wegovy or Zepbound, Noom's team submits a prior authorization request to your insurer on your behalf, then you wait for a decision.
Noom's separate GLP-1Rx track (including its Microdose and Plus tiers) works differently: compounded semaglutide is included directly in a flat monthly price, generally $99 to $299/month depending on tier, with no insurance billing and no prior authorization step at all. The tradeoff is the same one that runs through this entire category: insurance-dependent pricing can be cheaper if approved, but carries real timeline risk; flat-rate compounded pricing is more expensive on paper for some patients but removes the waiting entirely.
The prior authorization timeline, in practice
Put together, a worst-case scenario — denial followed by a full appeal — can mean roughly three months between your first telehealth visit and an actual coverage decision. That's not a criticism of Noom specifically; it reflects how prior authorization and appeals work across the industry for any provider billing GLP-1s through insurance.
Coverage by Plan Type
| Plan Type | Typical Coverage | What Slows Approval |
|---|---|---|
| Large employer (5,000+) | More common (~43%) | Still often requires BMI/comorbidity documentation |
| Small/mid employer (200+) | Less common (~19%) | Category exclusions defeat any PA regardless of docs |
| ACA Marketplace | Rare for obesity brands | Formulary tier restrictions |
| Medicare Part D | Not covered by law | Weight-loss PA denied by statute |
What to Do While You Wait
- Ask what documentation was submitted and whether step therapy is required
- Call your insurer to confirm receipt and get an expected decision date
- Ask about expedited review if a treatment gap is a clinical concern
- Consider Noom's own compounded track as a bridge
- Get the denial reason in writing before deciding whether to appeal
- A 90-day appeal means roughly a full quarter without your intended medication
- Weigh a flat-rate compounded option against the cost of waiting
- Ask your new prescriber about dose-continuity to avoid restarting titration
Deciding Whether to Wait or Switch: 5 Steps
1. Confirm which Noom Med track you're actually on. Branded PA timelines don't apply if you're on the compounded GLP-1Rx track.
2. Call your insurer and ask if weight-loss GLP-1s are excluded at the plan level. If so, waiting through PA won't change the outcome.
3. If your plan does cover the category, get a specific timeline estimate and set a personal deadline.
4. Price out a flat-rate compounded option in parallel so you have a fallback ready the moment your deadline passes.
5. If you do switch, bring your current dose and titration history to your new prescriber to avoid losing progress.
Noom Med vs. Luma Health: Where Each Fits
Luma Health's compounded semaglutide and tirzepatide are priced flat at $197/month and $297/month, with no insurance billing and therefore no prior authorization to wait on. Compared against Noom Med's own compounded GLP-1Rx tiers, which range roughly $99 to $299/month depending on plan, pricing is broadly comparable at the top end, and Noom can be less expensive at its lower Microdose tier. The meaningful difference isn't price so much as dosing structure and total wait-time risk on the branded path.
No insurance billing means no prior authorization to wait on. Compounded semaglutide is $197/month and compounded tirzepatide is $297/month, flat, prepared by VialsRX, TX Board #35264, verifiable directly with the board. See all treatment options →
No prior authorization,
no waiting on a decision
$197/month semaglutide. $297/month tirzepatide. Flat price, no insurance decision to wait on.
Get Started → Or start your free health assessmentWhat the Clinical Evidence Actually Supports
Prior authorization timelines are an insurance-process question, entirely separate from the underlying clinical evidence. Semaglutide's weight-loss efficacy comes from the STEP program, including STEP 1, which showed average weight reductions of roughly 15% over 68 weeks. Cardiovascular outcome data comes from the SELECT trial, which followed over 17,000 patients with established cardiovascular disease and found a measurable reduction in major adverse cardiac events.
Tirzepatide's data comes from the SURMOUNT program, including SURMOUNT-1, which showed average weight reductions ranging from 15% to nearly 21% depending on dose. Head-to-head comparison data against semaglutide comes from the SURPASS-2 trial, which found tirzepatide produced somewhat greater average weight loss at equivalent points in treatment.
Whatever track you end up on with Noom Med, or whichever provider you choose more broadly, this underlying evidence base doesn't change. What changes is access, timeline, and total cost — which is exactly why it's worth separating the insurance question from the medical one when you're deciding how to proceed.
Frequently Asked Questions
For branded medications, initial decisions commonly take up to two weeks. If denied and appealed, that process can take up to an additional 90 days — a worst-case timeline of roughly three months.
No. Noom's compounded track is priced as a flat monthly fee that includes medication, so there's no insurance billing and no prior authorization step.
You can appeal (typically up to 90 days) or switch to a cash-pay option while you decide. Get your denial reason in writing first, since a hard plan-level exclusion is unlikely to be overturned.
Usually yes, in terms of time to start treatment. Whether it's cheaper overall depends on your specific insurance benefits.
No. Luma Health's compounded medications are priced flat and billed directly to you, so there's no prior authorization process or approval wait involved.
Against Noom's compounded tiers ($99–$299/month), pricing is broadly comparable. Against Noom's branded track, it depends entirely on your insurance approval and copay.
References
- US News Health. Noom GLP-1 Weight Loss Review 2026. health.usnews.com
- Noom. Noom Med Plans & Pricing. noom.com/med/pricing
- Peterson-KFF Health System Tracker. Perspectives from Employers on Covering GLP-1 Agonists (2025). healthsystemtracker.org
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- Texas State Board of Pharmacy. License Verification — VialsRX #35264. pharmacy.texas.gov